Opsonophagocytic assays (OPAs) are routinely used for assessing the immunogenicity of 20 pneumococcal vaccines, with OPA data often utilized for licensure of new vaccine formulations. 21
To meet these goals, six participating laboratories tested a panel of sera in five runs for 13 27 serotypes. For each serum, consensus OIs were obtained using a mixed effects ANOVA 28 model. For the calibration sera, normalized consensus values were also determined based on 29 007sp. 30
For each serotype, the overall reduction in inter-laboratory variability was calculated by 31 comparing the coefficients of variation of the unadjusted and the normalized values. 32
Normalization of the results substantially reduced the inter-laboratory variability, ranging from a 33 15% reduction in variability for serotype 9V to 64% for serotype 7F. Normalization also 34 increased the proportion of data within 2-fold of the consensus value from approximately 70% 35 (average of all serotypes) to >90%. 36
Based on the data obtained in this study, Pneumococcal Reference Standard Lot 007sp will 37 likely be a useful reagent for normalizing pneumococcal OPA results from different laboratories. 38
The data also support the use of the 16 FDA OPA calibration sera as part of the initial 39 evaluation of new assays or periodic assessment of established assays. 40
INTRODUCTION 43
Conjugate vaccines targeting the capsular polysaccharides (PSs) of Streptococcus pneumoniae 44 have been largely successful in reducing the incidence of invasive pneumococcal disease 45 caused by vaccine serotypes in various countries throughout the world, in both children and 46 adults (reviewed in (1)). Although large clinical trials were performed to demonstrate the 47 efficacy of the first pneumococcal conjugate vaccine, such efficacy trials are not practical for the 48 evaluation of new generation vaccines with increased serotypic coverage. Therefore, surrogate 49 markers of protection have been used to evaluate new vaccine formulations. 50
51
Comparison of the immunogenicity of a prospective vaccine to that of the current vaccine in 52 terms of serotype-specific IgG concentrations using ELISA has been utilized in assessing the 53 efficacy of candidate vaccines in pediatric populations. Since a correlation between serum 54 antibody concentrations and vaccine efficacy has been established only for this age group (2), 55 the use of ELISA for the evaluation of vaccine efficacy is restricted to pediatric populations. 56
Although the development of a third generation ELISA (reviewed in (3)) has increased the 57 specificity of the assay, serum antibody concentrations measured in ELISA may not always 58 reflect their functional capacity, especially in adults (4, 5) . Therefore, ELISA data is not 59 accepted for licensure of pneumococcal vaccines in adults. 60
61
In vivo, antibodies against pneumococcal capsular PS are thought to function by opsonizing the 62 bacteria for subsequent phagocytosis and killing by granulocytes (6). Thus, in vitro 63 opsonophagocytic killing assays (OPAs) were developed to mimic this mechanism (7-9). 64
Multiple improvements have since been made to the assay, resulting in various assay protocols 65 (10, 11), including a multiplexed format (MOPA) (12), that are suitable for vaccine studies. 66
69
A previous international inter-laboratory OPA study (13) showed a reasonably good correlation 70 between results obtained by different labs that utilize different assays formats. However, the 71 absolute agreement of the results was less than desirable with a 2-fold range above and below 72 the consensus values (i.e., a 4-fold range from the upper limit to the lower limit) encompassing 73 approximately 68% of the results. A 4-fold range above and below the consensus value (i.e., a 74 16-fold range from upper limit to lower limit) was needed to capture approximately 90% of the 75 results. The study authors concluded that OPAs may need additional control and absolute OPA 76 results were not necessarily comparable among different laboratories. 77
78
When the new pneumococcal ELISA reference serum, 007sp, was produced, it was intended to 79 serve as a reference serum for both ELISAs and OPAs (14) . When sera were pooled to create 80 007sp, sixteen single-donor sera were prepared for OPA calibration purposes (14). In 2012, an 81 international collaborative study involving 6 laboratories familiar with OPAs was devised to: 1) 82
assign consensus values to 007sp and a panel of 16 sera to be used for calibrating OPAs; and 83 2) determine if normalization of results with 007sp had any impact on the inter-laboratory 84 agreement of OPA results. Herein described are the results of the collaboration. 85 86 87
MATERIALS AND METHODS 88
Participating laboratories. The locations and the formats used by each of the six laboratories 89 selected to participate are indicated in Table 1 . Note, the laboratories are listed alphabetically in 90 Table 1 and this order is not associated with the letter designations (A-F) utilized throughout this 91 manuscript. Participation in the study was limited to laboratories with substantial experience 92 with pneumococcal OPAs that were routinely performing the assays.
Sera. The production of 007sp and the 16 FDA OPA calibration sera (samples 007A through 95 007P) have been described previously (14) . 96 97 Preliminary data (data not shown) indicated that for many serotypes, the calibration sera panel 98 lacked samples with relatively low opsonization indexes (OIs, defined below). Four 99 unvaccinated sera (15) that were included in those preliminary runs to serve as low OI samples 100 produced irregular killing curves for multiple serotypes, and thus were not useful for this 101 purpose. So that samples with low OIs could be included in this evaluation, four low OI samples 102 were prepared by spiking a calibration serum into an immunoglobulin-depleted serum (IDS). 103
The IDS purchased from BBI Solutions (Cardiff, UK) possessed some residual opsonic activity 104 against some serotypes. Additional IgM depletion was performed using affinity chromatography 105 (16) until the residual opsonic activity was removed. One set of four sera was prepared for 106 serotypes 4, 6B, 14, and 19A (sera S17, S18, S19, and S20); and a second set of four sera was 107 prepared for the remaining 9 serotypes (sera S21, S22, S23, and S24). 108 same for all laboratories utilizing the MOPA, but were different for each of the laboratories using 121 the singleplex format. 122
123
For each result, the OI was calculated and tabulated by the participating laboratory. Although 124 different algorithms were utilized to determine the OI, all laboratories defined an OI as the 125 estimated dilution of serum that kills 50% of the target bacteria. Control wells (defining 0% 126 killing) containing target bacteria, complement, and HL60 cells (no test serum) were included in 127 every assay. Results that failed to meet a laboratory's assay system suitability criteria were 128 indicated as "Indeterminable" ( laboratory GMOI was defined to be an inter-laboratory outlier if it differed from its corresponding 151 consensus OI by >4-fold. If, for each combination of sample and serotype, more than one 152 laboratory OI was >4-fold from the consensus OI, then only the most extreme difference was 153 identified as the outlier. Inter-laboratory outliers are listed in Table 2 and are indicated in red 154 font in Supplementary Table S1 . 155
156
For individual calibration samples, the percent reduction in inter-laboratory variability due to 157 normalization was calculated as components for the normalized OIs. In cases where the total variability for the normalized OIs 161 exceeded that for the non-normalized OIs, the percent reduction in inter-laboratory variability 162 due to normalization was calculated as
To estimate the percent reduction in inter-laboratory variability due to normalization across the 165 set of calibration samples, the log transformed OIs and normalized OIs were fit using a mixed 166 effects ANOVA model containing terms for Lab, Sample, Sample×Lab, Run(Lab), 167
Sample×Run(Lab). Sample was regarded as a fixed effect and all other terms as random 168 effects. The percent reduction in inter-laboratory variability due to normalization was calculated 
denote the corresponding variance components for the normalized OIs. 173
RESULTS 175
007sp consensus values 176
In order to estimate the 007sp consensus values, the 007sp OIs were fit using a mixed effects 177 ANOVA model. For each of the 13 target serotypes, the individual laboratory geometric mean 178
OIs (GMOIs) as well as the consensus value for 007sp are shown in Table 3 and Figure 1 . The 179 consensus values ranged from 229 (for serotype 3) to 7776 (serotype 7F). The width of the 180 95% confidence intervals (CIs) ranged from 1.9-fold for serotype 6A to >10-fold for serotype 181
19A. The confidence intervals for the other serotypes were generally in the 2-to 3-fold range 182 except for serotype 18C and 23F which had confidence intervals of 5.2-and 4.8-fold, 183
respectively. 184
185
The total coefficient of variation (CV, expressed as a percentage) and various variance 186 components (Lab, Run(Lab), and Plate (RunxLab)) estimated from the ANOVA are also shown 187
in Table 3 . Serotype 5 had the lowest CV (48%), and serotype 19A had the highest CV (163%). 188
Serotypes 18C and 23F also had relatively high total CVs (127% and 117%, respectively). The 189 total CVs of the remaining serotypes were generally in the 60-80% range. The variance 190 components analysis showed that the laboratory ("Lab" in Table 2 ). The laboratory specific GMOIs 201 (unadjusted and normalized) for each of the calibration sera are included in Supplementary 202 Table S1 with the 20 results identified as outliers indicated in red. Generally, the confidence 203 intervals for the normalized consensus values are quite small, with most less than 2-fold. 204 205
Effect of normalization on inter-laboratory variation 206
To determine the effect of normalization on assay variation, the variability of the unadjusted 207 results (including inter-laboratory outliers) from the 20 test sera was compared to the variability 208 of the normalized results (also including outliers). For each of the 13 target serotypes, the 209 variability (expressed as %CV) of the unadjusted and normalized results is presented in Table  210 5. The percent reduction in variability due to normalization, as well as various variance 211 components estimated by the ANOVA, are also indicated in Table 5 (see Supplementary Table  212 S2 for the effect of normalization on individual samples). A noticeable improvement in inter-213 laboratory agreement with normalization based on 007sp performance was seen, ranging from 214 a 15% reduction in variability for serotype 9V to 64% for serotype 7F. Although the CVs were 215 still high for some serotypes after normalization (for example, for serotype 23F, the CV 216 decreased from 244% to 180% with normalization), the four mock low OI sera are responsible 217 for the high CVs in many instances. The data in Figure 2 also indicate that the benefit of normalization may be dependent on the OI. 229
For the sera with low consensus values, normalization provided little benefit. In fact, the 230 variability increased for the low OI sera in several instances. 231
232
The effect of normalization can also be seen by comparing the breadth of the confidence 233 intervals for the calibration sera in Supplementary Table S2 , where normalization reduced the 234 confidence interval for most samples and most serotypes. For some serotypes (19A, for 235 example), the effect is quite striking. 236
237
The effect of normalization for each serotype was also assessed by determining the percentage 238 of laboratory specific GMOIs (with and without normalization) within 2-and 3-fold of the 239 consensus OI for the 16 FDA OPA calibration sera samples. The resulting percentages 240 combined over the set of laboratories are provided in Table 6 . Table 6 also includes the fold 241 range (above and below the overall consensus OIs) needed to encompass 90% of the results 242 was calculated. Normalization resulted in consistently higher percentages of results within 2-243 and 3-fold of the consensus values, with the increase in results within 2-fold most pronounced. 244
For example, for serotype 19A, the percentage of estimates within 2-fold increases from 56% to 245 91%. 246
247
A similar assessment was also performed for each individual laboratory. The percentages for 248 the individual laboratory assessments are presented in 
Effect of normalization on intra-laboratory variation 253
As a secondary goal of this study, the impact of standardization on intra-laboratory variation was 254 also examined. The calibration sera results from each run were normalized using the 007sp 255 results from the corresponding run and the 007sp consensus OI. For each combination of 256 laboratory and serotype, the overall intra-laboratory %CV was calculated, with and without 257 normalization, and the reduction in variability due to normalization was determined (see 258
Supplemental Table S3 ). The results varied considerably, ranging from a 71% reduction in 259 variation (Lab D, serotype 9V) to a 69% increase in variation (Lab E, serotype 9V), with no 260 obvious trend for a particular laboratory nor a particular serotype. 261
262

DISCUSSION 263
In this study, we describe the results of an international collaborative study with two primary 264 goals: 1) assign consensus values for a pneumococcal OPA standard and the FDA OPA 265 calibration sera; and 2) determine the impact of normalization with the OPA standard. 266
267
Although different assay formats and lots of reagents were used in this study, we were able to 268 assign the consensus values for 007sp with relatively narrow confidence intervals, suggesting 269 that pneumococcal OPAs produce consistent results despite variations in assay formats and 270 materials among laboratories. For 007sp, there was more variability associated with the 271 consensus values for 18C, 19A, and 23F. For serotypes 18C and 19A, the increased variability 272 was mostly driven by one laboratory (Laboratory E for 18C and Laboratory F for 19A, see Table  273 3 and Figure 1 ). The source of the higher variability for serotype 23F is not clear. 274
275
Generally, the confidence intervals for the unadjusted results of the FDA OPA calibration sera 276 were comparable to those of 007sp. However, normalization substantively reduced the size of 277 on October 29, 2017 by guest http://cvi.asm.org/ Downloaded from the confidence intervals, with most being less than 2-fold. Both model-based and frequency-278 based approaches suggested a considerable benefit to normalization in regards to inter-279 laboratory agreement. The results of the ANOVA indicate at least a 15% reduction in variability 280 due to normalization with 007sp. For the frequency-based approach, the percentage of results 281 within 2-and 3-fold of the consensus values for the 16 calibration sera increases substantially 282 (especially within 2-fold of the consensus values) after normalization (see Table 6 ). 283 284 However, the data in Figure 2 indicate that the benefit of normalization may be dependent on 285 the magnitude of the OI. Normalization did not improve the agreement for samples with low OIs 286 as some labs were not able to detect OIs for these samples. Since undetectable values cannot 287 be normalized, normalization provides little benefit for these low OI sera. Moreover, the 288 confidence intervals of unadjusted estimates for these low titer sera were higher than the 289 calibration sera. The fact that the sera with low OIs are not naturally incurred (i.e., they were 290 created by spiking high OI sera into a negative matrix) may contribute to the increase in 291 variability. Also, the high degree of variability in these sera may be due to the differences in the 292 sensitivity of assays used by different laboratories. 293
294
Applying the frequency-based method to the unadjusted data, the percentage of results within 295 2-fold of the consensus values varied by serotype, ranging from 56% (serotypes 19A and 23F) 296 to 91% (serotype 14), see Table 6 . Although differences among individual serotypes were 297 seen, the average of the 13 serotypes (~73%) is quite consistent with that of a previously 298 published study examining the inter-laboratory agreement of OPA data (13) which found that 299 approximately 68% of the results were within 2-fold of consensus values. Based on the results 300 of the previously published study and this study, approximately 70% of the results can be 301 expected to be within 2-fold of the consensus value when unadjusted OPA results from different However, our data suggest that normalization can improve overall agreement with more than 304 90% (average across all serotypes) of the results within 2-fold of the consensus value. In the 305 previous study (13), a 4-fold range above and below (16-fold overall) the consensus value was 306 needed to encompass 90% of the results. 307
308
As noted in the method section, normalization of sample data was based on the performance of 309 007sp on the same assay plate. In order to maximize assay throughput and minimize 310 consumption of 007sp, two alternate analytical approaches were also evaluated: normalizing 311 the data using the average 007sp result from all plates in a run; and normalizing the data using 312 the 007sp result from the first plate of a run. Normalization using either the 007sp OI from the 313 same assay plate or the 007sp OI run average performed similarly in terms of reducing the 314 variation between laboratories (data not shown). However, normalization based on 007sp 315 performance on only the first assay plate was less effective in reducing the variation (data not 316 shown). Therefore, ideally, 007sp would be included 2-3 times in each run. 317
318
As a secondary objective of the study, the effect of normalization on intra-laboratory variation 319 was examined. As shown in Supplementary Table S3 , the effect of normalization ranged from a 320 71% decrease in variability to a 69% increase in variability. Although there was no obvious 321 advantage to this approach, the data for this study was collected over a relatively short time 322 frame. Normalization may be useful for improving long-term assay stability when implemented 323
properly. However, normalization should be used cautiously when qualifying new reagents or 324 operators to ensure that it does not mask potential shifts in assay performance. 325
326
We see two primary limitations of this study. First, although each participating laboratory was 327 quite experienced with OPAs, the degree and depth of assay validation varied amongst the 328 participating laboratories. Simply using 007sp as a reference standard does not guarantee that every laboratory will generate comparable results. Second, the range of OIs of the calibration 330 sera was limited for some serotypes, and generally lacked low OIs. 331
332
Based on the data generated in this study we believe that 007sp may be a useful reference to 333 normalize data across laboratories. We found the most efficient method for normalization to be 334 the use of the 007sp consensus value and the average of the within run estimates using the 335 formula: 338
The data also support the use of the 16 FDA OPA calibration sera as part of the initial 339 evaluation of new assays or periodic assessment of established assays. The level of agreement 340 between the laboratory values and the consensus values reported here may help a laboratory 341 evaluate the performance of its assays. 342
343
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on October 29, 2017 by guest Table 1 . Participating laboratories and assay formats. The affiliation and location of each participating laboratory is indicated. The assay format (including reference) utilized is also indicated. Note, laboratories are listed alphabetically and this order is not associated with the letter designations (A-F) utilized throughout this manuscript. 30% Pn, pneumococcal serotype; CV, coefficient of variation (expressed as a percent); Lab, variability among the laboratories; Run(Lab), variability among runs within each laboratory; LabxSample, variability associated with the interaction between test sample and laboratory; SamplexRun(Lab), variability associated with the interaction between test sample and runs within a laboratory. Table 6 . Frequency-based assessment of the effect of normalization. The percentage of laboratory-specific OIs within 2-and 3-fold of the overall consensus value is shown below. The fold range from the overall consensus needed to include 90% of the values ("Fold (90%")) is also shown. Outlier results are included in this analysis. Table 7 . Frequency-based assessment of normalization for individual laboratories. For each laboratory, the percentages of results within 2-and 3-fold of the consensus values listed in Table 4 are indicated. Outliers were included in these analyses. Results less than 80% for 2-fold are indicated by gray shading. 
